A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer - Trial NCT06382129
Access comprehensive clinical trial information for NCT06382129 through Pure Global AI's free database. This Phase 3 trial is sponsored by Sichuan Baili Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 558 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sichuan Baili Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 3
May 01, 2024
May 01, 2026
Primary Outcome
Overall survival (OS),Progression-free survival (PFS)
Summary
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate
 the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR
 wild-type non-small cell lung cancer after failure of anti-PD-1/PD-L1 monoclonal antibodies
 and platinum-based chemotherapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06382129
Non-Device Trial